N-[4-((R)-4-Methyl-6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenyl]-acetamide (Compound)

Pubchem:PUBCHEM:9816296

Id:9342d1cf-1be1-52bd-969c-8453560ebc0c

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View N-[4-((R)-4-Methyl-6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenyl]-acetamide's neighborhood in the knowledge graph.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for N-[4-((R)-4-Methyl-6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenyl]-acetamide.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with N-[4-((R)-4-Methyl-6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenyl]-acetamide.

Results found

Linked to

	Label	Description
	N-[4-((R)-4-Methyl-6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenyl]-acetamide bioactivity cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from IDG
	N-[4-((R)-4-Methyl-6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenyl]-acetamide bioactivity cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from IDG

N-[4-((R)-4-Methyl-6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenyl]-acetamide bioactivity cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B

Knowledge Graph Assertion (Entity type)

A Knowledge Graph Assertion from IDG

N-[4-((R)-4-Methyl-6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenyl]-acetamide bioactivity cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A

Knowledge Graph Assertion (Entity type)

A Knowledge Graph Assertion from IDG

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2025

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.